Merck Buys Idenix And Their Drug For Hepatitis C

Marcie Sillman talks to biotech journalist Luke Timmerman about the pharmaceutical company Merck buying the biotech company Idenix for over $3 billion and what that means for the future of a hepatitis C treatment. Also, they discuss the latest from the American Society Of Clinical Oncology meeting.